Skip to main content
main-content

12-10-2020 | Gastroenterology | Video

UEGW 2020 | Ultraproactive therapeutic drug monitoring does not outperform reactive in IBD

Peter Bossuyt discusses his pragmatic trial looking at the potential of ultraproactive therapeutic drug monitoring to improve infliximab dosing in patients with inflammatory bowel disease (5:38).

Funding for independent interviews at UEG Week Virtual 2020 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Image Credits